SCHEMBL7127630

SCHEMBL7127630

[O-][n+]1ccc2c(-c3ccc(F)cc3)cccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
PTGS2 P35354 3/20 0.39
PTGS1 P23219 1/20 0.39
CYP17A1 P05093 1/20 0.37
TDO2 P48775 1/20 0.37
ENPP1 P22413 1/20 0.35
GPR84 Q9NQS5 2/20 0.34
MAPK14 Q16539 2/20 0.34
MAPK13 O15264 1/20 0.34
GCGR P47871 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
ACHE P22303 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
NR4A2 P43354 1/20 0.33
FABP1 P07148 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6996810 0.85 CA12 (0.42) CA12CA1CA2CA9PTGS2
SCHEMBL20292597 0.75 GPR84 (0.37) TDO2GPR84ACHE
SCHEMBL7118826 0.75 TMIGD3 (0.36) CA12CA1CA2CA9ENPP1
SCHEMBL18805039 0.75 CA12 (0.53) CA12CA1CA2CA9PTGS2
SCHEMBL8074741 0.75 CA12 (0.53) CA12CA1CA2CA9PTGS2
SCHEMBL26750929 0.73 CA12 (0.51) CA12CA1CA2CA9PTGS2
SCHEMBL26750922 0.72 CA12 (0.50) CA12CA1CA2CA9PTGS2
SCHEMBL11310675 0.72 ALDH1A1 (0.50) GPR84NR4A2
SCHEMBL4517846 0.71 ALDH1A1 (0.45) MET
SCHEMBL28541702 0.70 PTGS2 (0.38) CA12CA1CA2CA9PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 CA12 230/4885CA1 487/4885CA2 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.